Tags

Type your tag names separated by a space and hit enter

BioEnterics Intragastric Balloon: The Italian Experience with 2,515 Patients.
Obes Surg. 2005 Sep; 15(8):1161-4.OS

Abstract

BACKGROUND

The temporary use of the BioEnterics Intragastric Balloon (BIB) in morbidly obesity is increasing worldwide. The aim of this study is the evaluation of the efficacy of this device in a large population, in terms of weight loss and its influence on co-morbidities.

METHODS

Data were retrospectively recruited from the data-base of the Italian Collaborative Study Group for Lap-Band and BIB (GILB). After diagnostic endoscopy, the BIB was positioned and was filled with saline (500-700 ml) and methylene blue (10 ml). Patients were discharged with diet counselling (approximately 1000 Kcal) and medical therapy. The BIB was removed after 6 months. Positioning and removal were performed under conscious or unconscious sedation. Mortality, complications, BMI, %EWL, BMI loss and co-morbidities were evaluated.

RESULTS

From May 2000 to September 2004, 2,515 patients underwent BIB (722M/1,793F; mean age 38.9+/-14.7, range 12-71; mean BMI 44.4+/-7.8 kg/m(2) ; range 28.0-79.1; and mean excess weight 59.5+/-29.8 kg, range 16-210). BIB positioning was uncomplicated in all but two cases (0.08%) with acute gastric dilation treated conservatively. Overall complication rate was 70/2,515 (2.8%). Gastric perforation occurred in 5 patients (0.19%), 4 of whom had undergone previous gastric surgery: 2 died and 2 were successfully treated by laparoscopic repair after balloon removal. 19 gastric obstructions (0.76%) presented in the first week after positioning and were successfully treated by balloon removal. Balloon rupture (n=9; 0.36%) was not prevalent within any particular period of BIB treatment, and was also treated by BIB removal. Esophagitis (n=32; 1.27%) and gastric ulcer (n=5; 0.2%) presented in patients without a history of peptic disease and were treated conservatively by drugs. Preoperative co-morbidities were diagnosed in 1,394/2,471 patients (56.4%); these resolved in 617/1,394 (44.3%), improved (less pharmacological dosage or shift to other therapies) in 625/1,394 (44.8%), and were unchanged in 152/1,394 (10.9%). After 6 months, mean BMI was 35.4+/-11.8 kg/m(2) (range 24-73) and %EWL was 33.9+/-18.7 (range 0-87). BMI loss was 4.9+/-12.7 kg/m(2) (range 0-25).

CONCLUSIONS

BIB is an effective procedure with satisfactory weight loss and improvement in co-morbidities after 6 months. Previous gastric surgery is a contraindication to BIB placement.

Authors+Show Affiliations

Italian Group for Lap-Band, Fondazione IDIS - Città della Scienza, Naples, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16197790

Citation

Genco, A, et al. "BioEnterics Intragastric Balloon: the Italian Experience With 2,515 Patients." Obesity Surgery, vol. 15, no. 8, 2005, pp. 1161-4.
Genco A, Bruni T, Doldi SB, et al. BioEnterics Intragastric Balloon: The Italian Experience with 2,515 Patients. Obes Surg. 2005;15(8):1161-4.
Genco, A., Bruni, T., Doldi, S. B., Forestieri, P., Marino, M., Busetto, L., Giardiello, C., Angrisani, L., Pecchioli, L., Stornelli, P., Puglisi, F., Alkilani, M., Nigri, A., Di Lorenzo, N., Furbetta, F., Cascardo, A., Cipriano, M., Lorenzo, M., & Basso, N. (2005). BioEnterics Intragastric Balloon: The Italian Experience with 2,515 Patients. Obesity Surgery, 15(8), 1161-4.
Genco A, et al. BioEnterics Intragastric Balloon: the Italian Experience With 2,515 Patients. Obes Surg. 2005;15(8):1161-4. PubMed PMID: 16197790.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - BioEnterics Intragastric Balloon: The Italian Experience with 2,515 Patients. AU - Genco,A, AU - Bruni,T, AU - Doldi,S B, AU - Forestieri,P, AU - Marino,M, AU - Busetto,L, AU - Giardiello,C, AU - Angrisani,L, AU - Pecchioli,L, AU - Stornelli,P, AU - Puglisi,F, AU - Alkilani,M, AU - Nigri,A, AU - Di Lorenzo,N, AU - Furbetta,F, AU - Cascardo,A, AU - Cipriano,M, AU - Lorenzo,M, AU - Basso,N, PY - 2005/10/4/pubmed PY - 2005/12/24/medline PY - 2005/10/4/entrez SP - 1161 EP - 4 JF - Obesity surgery JO - Obes Surg VL - 15 IS - 8 N2 - BACKGROUND: The temporary use of the BioEnterics Intragastric Balloon (BIB) in morbidly obesity is increasing worldwide. The aim of this study is the evaluation of the efficacy of this device in a large population, in terms of weight loss and its influence on co-morbidities. METHODS: Data were retrospectively recruited from the data-base of the Italian Collaborative Study Group for Lap-Band and BIB (GILB). After diagnostic endoscopy, the BIB was positioned and was filled with saline (500-700 ml) and methylene blue (10 ml). Patients were discharged with diet counselling (approximately 1000 Kcal) and medical therapy. The BIB was removed after 6 months. Positioning and removal were performed under conscious or unconscious sedation. Mortality, complications, BMI, %EWL, BMI loss and co-morbidities were evaluated. RESULTS: From May 2000 to September 2004, 2,515 patients underwent BIB (722M/1,793F; mean age 38.9+/-14.7, range 12-71; mean BMI 44.4+/-7.8 kg/m(2) ; range 28.0-79.1; and mean excess weight 59.5+/-29.8 kg, range 16-210). BIB positioning was uncomplicated in all but two cases (0.08%) with acute gastric dilation treated conservatively. Overall complication rate was 70/2,515 (2.8%). Gastric perforation occurred in 5 patients (0.19%), 4 of whom had undergone previous gastric surgery: 2 died and 2 were successfully treated by laparoscopic repair after balloon removal. 19 gastric obstructions (0.76%) presented in the first week after positioning and were successfully treated by balloon removal. Balloon rupture (n=9; 0.36%) was not prevalent within any particular period of BIB treatment, and was also treated by BIB removal. Esophagitis (n=32; 1.27%) and gastric ulcer (n=5; 0.2%) presented in patients without a history of peptic disease and were treated conservatively by drugs. Preoperative co-morbidities were diagnosed in 1,394/2,471 patients (56.4%); these resolved in 617/1,394 (44.3%), improved (less pharmacological dosage or shift to other therapies) in 625/1,394 (44.8%), and were unchanged in 152/1,394 (10.9%). After 6 months, mean BMI was 35.4+/-11.8 kg/m(2) (range 24-73) and %EWL was 33.9+/-18.7 (range 0-87). BMI loss was 4.9+/-12.7 kg/m(2) (range 0-25). CONCLUSIONS: BIB is an effective procedure with satisfactory weight loss and improvement in co-morbidities after 6 months. Previous gastric surgery is a contraindication to BIB placement. SN - 0960-8923 UR - https://www.unboundmedicine.com/medline/citation/16197790/BioEnterics_Intragastric_Balloon:_The_Italian_Experience_with_2515_Patients_ L2 - https://dx.doi.org/10.1381/0960892055002202 DB - PRIME DP - Unbound Medicine ER -